MetaCap

ALX Oncology (ALXO) vs Eledon Pharmaceuticals (ELDN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Eledon Pharmaceuticals (ELDN) has outperformed ALX Oncology (ALXO) over the past year, gaining 23.6% versus a loss of 25.9%. Over five years, ELDN leads with a -65.6% price change compared with -96.8% for ALXO. Eledon Pharmaceuticals is the larger company by market cap ($150.3 million vs $137.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALXO-25.87%ELDN+23.61%
+204%+77%-49%
Nov 21, 20251 yearNov 20, 2026
ALXO-97.23%ELDN-66.48%
+5%-49%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALXO versus ELDN key metrics
MetricALXOELDN
Share price$1.06$1.78
Market cap$137.03M$150.34M
1-day change+3.92%-6.32%
YTD return-6.19%+17.88%
1-year return-25.87%+23.61%
5-year return-96.84%-65.64%
EPS (TTM)$-0.87$-0.73
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-101.69M$-45.62M
52-week high$2.66$4.49
52-week low$0.862$1.39
Distance from 52-week high-60.15%-60.36%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+333.96%+405.62%
Average volume1.19M931.77K
Shares outstanding129.27M84.46M
Employees4933
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ELDN has outperformed ALXO by 49.5 percentage points over the past year.

About ALX Oncology

ALXO stock →

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees

About Eledon Pharmaceuticals

ELDN stock →

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company.

Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees

ALXO vs ELDN FAQ

Which is bigger, ALX Oncology or Eledon Pharmaceuticals?

Eledon Pharmaceuticals (ELDN) is larger, with a market capitalization of $150.34M compared with $137.03M for ALX Oncology (ALXO).

Which stock has performed better over the past year, ALXO or ELDN?

ELDN returned +23.61% over the past 12 months, compared with -25.87% for ALXO (price return, excluding dividends). Past performance does not predict future results.

Are ALX Oncology and Eledon Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons